Last reviewed · How we verify
NCT07189923
Comparative Real-world Study on Ablative Fractional CO₂ Laser vs PRP With Microneedling for Acne Scar Treatment.
NA trial testing Ablative Fractional CO₂ Laser in Acne Scars in 116 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | Dr. Sirajul Islam Medical College |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 116 |
| Start date | 1 December 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Ablative Fractional CO₂ Laser
- Platelet-Rich Plasma (PRP) With Microneedling
Conditions studied
- Acne Scars — all drugs for Acne Scars →
- Ablative Fractional CO₂ Laser Therapy — all drugs for Ablative Fractional CO₂ Laser Therapy →
- Platelet-rich Plasma (PRP) — all drugs for Platelet-rich Plasma (PRP) →
Sponsor
Dr. Sirajul Islam Medical College
Who can join
18 and older, any sex, with Acne Scars or Ablative Fractional CO₂ Laser Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Road traffic accidents (RTAs) remain a major public health concern worldwide and in Bangladesh, contributing significantly to injury, disability, and premature death. In resource limited settings like Bangladesh, it is crucial to understand the factors that influence survival following an RTA in order to develop effective prevention strategies and improve patient outcomes. Therefore, this study aims to determine the 30 day survival rate and identify predictors of survival among adult RTA victims treated at a tertiary care hospital in Bangladesh. The observational study will be carried out at Emergency and casualty department of Dhaka Medical College Hospital (DMCH) between October 2025 and March 2026. A total of 204 adults (≥18 years) presenting to the hospital's Casualty Department with RTA related injuries will be included. Informed written consent will be obtained from each patient or their legal guardian prior to enrollment. Data will be collected through structured face to face interviews, review of hospital records, and follow up on the 30th day of accident. The follow-up will be conducted either in person or by telephone. Variables will include patient demographics, accident circumstances, admission characteristics, injury pattern and severity, pre-hospital care, clinical condition at admission, hospital management provided, and treatment outcome. All data will be analyzed using SPSS version 25.0. Kaplan-Meier analysis will estimate survival probabilities, while Cox proportional hazards regression will be used to identify independent predictors of mortality. The findings of this study are expected to generate context-specific, evidence-based insights for strengthening trauma care protocols, gap related to emergency handling of the RTA patients, enhancing pre-hospital emergency services, and informing policy decisions aimed at reducing preventable RTA-related mortality and morbidity in Bangladesh.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07189923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acne Scars
Currently open trials in the same condition.
- NCT07368764 — The Suitability of Tience® for Treating Acne Scars · NA · recruiting
- NCT04807179 — Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07189923 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Sirajul Islam Medical College
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07189923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing